Daily Stock List
GraphOn Corp. (GOJO)
FeedBlitz, Stockpalooza, OTCPicks, OTC Advisors, PennyTrader Publisher, Nebula Stocks, and Stock Guru reported previously on GraphOn Corp. (GOJO), and today we report on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Campbell, California, GraphOn Corp. develops, markets, sells, and supports application virtualization software and cloud computing software for different computer operating systems. The Company is an innovator of cost-effective, advanced solutions that help customers’ access applications from anywhere. Their high-performance software solutions provide fast application access, cross-platform connectivity, and a centralized architecture that delivers a substantial lower cost of ownership.
GraphOn's GO-Global solutions can be used with Microsoft (MSFT) Windows, IBM AIX, Oracle (ORCL) Solaris, Hewlett-Packard (HPQ) HP-UX, Linux, Apple (AAPL) OS X and iOS, Google (GOOG) Android, and other operating systems. The GO-Global product family provides simple and secure application access solutions that extend the reach of their customers' Windows, UNIX, and Linux applications to their corporate networks or the Web.
GO-Global makes it easy to create a private cloud that allows authorized employees, business partners, and customers to securely access legacy applications from anywhere, regardless of connection, location, client platform, or operating system. GO-Global incorporates advanced server-centric technology. It is an efficient cross-platform solution that cost-effectively Web-enables centralized applications and documents for quick delivery to local, remote, and mobile users running Windows, Linux, UNIX, and OS X, iOS, Android or any Web browser. GO-Global-enabled applications retain 100 percent of their features, functions, as well as branding.
The Company's GO-Global for Windows delivers Windows applications to practically any platform. Their GO-Global for UNIX delivers UNIX and Linux applications to virtually any platform.
Last week, GraphOn announced the immediate availability of GO-Global 4.6 for Windows. GO-Global for Windows is a cross-platform solution; it delivers centralized Windows applications to almost any location, platform, and operating system as though the applications were running locally. With the included GO-Global Gateway component, the enterprise and large hosting providers can take complete advantage of Active Directory and load balancing. This is while scaling beyond the limits of the Company's stand-alone GO-Global Host software.
Mr. Christoph Berlin, GraphOn's Chief Operating Officer, said, "Further expanding our mobility capabilities, GO-Global 4.6 adds the ability for iOS clients such as iPad and iPhone to connect through our enterprise gateway solution. We've also broadened our client support with a Google Chrome Plug-in, compatibility updates for Internet Explorer 10 and Firefox 17, as well as a native client for Ubuntu."
GraphOn Corp. (GOJO), closed Tuesday's trading session at $0.65, up 3.17%, on 751,919 volume with 288 trades. The average volume for the last 60 days is 332,579 and the stock's 52-week low/high is $0.11/$0.7999.
Bontan Corporation, Inc. (BNTNF)
Stock Stars, SmallCapVoice, and HotStockChat reported previously on Bontan Corporation, Inc. (BNTNF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Founded in 1973, Bontan Corporation, Inc. looks for business opportunities in the biotechnology sector. Bontan has their corporate headquarters in Toronto, Ontario. The Company recently concluded a settlement on their indirect oil and gas interest in Israel and is focusing on biotechnology now. Bontan's shares trade on the OTC Markets' OTCQB.
In late March, Bontan announced that they signed a Letter Of Intent (LOI) with Portage Pharma Ltd., a private limited company formed under the laws of The British Virgin Islands (BVI) to acquire all the issued and outstanding shares of Portage in exchange for approximately 81.7 million shares of Bontan. Approximately 71.4 million shares of Bontan, equal to the total number of warrants and options presently issued and outstanding in Bontan, will be reserved for the shareholders of Portage to be issued as warrants and options on terms to be mutually agreed upon at the time of Closing.
Today, Bontan announced that they incorporated a newly formed company, Portage Acquisition, Inc. (PAI), incorporated under the laws of the British Virgin Islands (BVI). PAI is currently a wholly owned subsidiary of Bontan, and will facilitate early closing of the proposed acquisition of Portage Pharma by way of a BVI statutory merger.
Portage Pharma currently holds a master license to the Antennapedia platform for all pathologies (except oncology). Upon closing of the Portage Pharma acquisition, Bontan will engage in researching and developing products through to proof of concept with an early concentration on unmet clinical needs and orphan drugs. Bontan, following proof of concept, will look to sell or license the products to Big Pharma.
The Portage Board of Directors and key shareholders are Dr. Gregory Bailey, Mr. Jim Mellon and Dr. Declan Doogan. Portage has assembled a very experienced team of senior researchers and developers led by Dr. Bruce Littman, President and Chief Executive Officer, and Dr. Frank W. Marcoux, Chief Scientific Officer.
Bontan Corporation, Inc. (BNTNF), closed Tuesday's trading session at $0.28, up 12.90%, on 1,104,878 volume with 150 trades. The average volume for the last 60 days is 215,033 and the stock's 52-week low/high is $0.01/$0.25.
Real Estate Contacts, Inc. (REAC)
Greenbackers reported last week on Real Estate Contacts, Inc. (REAC), OtcWizard did earlier, and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
Headquartered in New Castle, Pennsylvania, Real Estate Contacts, Inc. conducts an online real estate advertising and marketing real estate website. This includes a real estate video listings network. The Company has their real estate search portal (www.realestatecontacts.com). Real Estate Contacts goal is to become one of the leading marketing partners to the real estate industry.
Real Estate Contacts conducts their business solely within the internet and the online video arena. This includes their real estate search engine, social community and video real estate network. The Company matches buyers, sellers, brokers and professionals anywhere in the world by way of their portal website.
Real Estate Contacts' business strategy is a user-friendly approach that allows the consumer to view listings of homes from the website and video channel of their local real estate office or agent. In addition, their website will feature no more than five agents per territory. Their policy in this regard will eliminate a substantial amount of the competition for the real estate agent, broker and office. The Company believes that their concept will have a high level of interest from real estate professionals.
The RealEstateContacts.com site consists of an array of well-known and local independently owned and operated franchisees of the nation's leading real estate companies. Additionally, it consists of individual real estate agents, local mortgage brokers and national mortgage lenders. RealEstateContacts.com is not in the real estate business. Consequently, it does not compete against professional real estate brokers or agents.
This past February, Real Estate Contacts announced that they are in the first stage of development for their new National Online Real Estate Video Channel. Real Estate Professionals having their own real estate video channel website will soon be available on www.realestatevideochannels.com.
Real Estate Contacts' new Real Estate Video Channel website will feature videos, slide shows and virtual tours of properties produced by the Company's individual affiliate channel owners. The national real estate video listings channel will have thousands of videos of homes for sale across the nation.
Real Estate Contacts, Inc. (REAC), closed Tuesday's trading session at $0.0269, up 407.55%, on 72,099,486 volume with 1,166 trades. The average volume for the last 60 days is 2,075,676 and the stock's 52-week low/high is $0.0015/$0.273.
Wiless Controls, Inc. (WILS)
Today, HotStockProfits reported on Wiless Controls, Inc. (WILS), and we are reporting on the Company as well, here at the QualityStocks Daily Newsletter.
Based in Montreal, Quebec, Wiless Controls, Inc. is a solution provider of M2M (Machine-to-Machine) wireless services designed to control and manage the access and use of almost any asset from "anywhere-to-anywhere" in the world. The Company is a pioneer in the market for embedded wireless tracking solutions that allow consumers and companies to reduce cost and increase control of remote assets. Wiless Controls' shares trade on the OTC Markets' OTCQB.
The Company's particular business model focuses on web-based device management, open standards, portability with carrier switching, integration with existing corporate Information Technology (IT) systems, and flexible revenue models with pay-per-use and no monthly or activation fees, to provide an optimal solution for many applications. The Wiless Controls M2M Platform moves information and commands from the source directly to the desktop or smartphone. It helps develop new service offerings, enables real-time control over assets and opens up new markets.
The Wiless Controls model includes seamless Wireless GSM coverage in more than 120 countries and network-ready, pre-activated embedded modules. The modular hardware designs support an assortment of wireless software radio technologies. The model additionally includes integrated on-board GPS tracking capabilities at no extra cost, a central management server for device monitoring and management, and over the air firmware upgrades. In addition, the model is network agnostic. A service model is available; it includes all cost of hardware, network and web services for a low monthly fee.
Today, Wiless Controls announced that they executed an agreement with JT Global to deliver the Company's Machine-to-Machine (M2M) platform on every continent using a guaranteed network connection. JT Global is a top worldwide network provider. JT Global's Resilience M2M platform combines numerous elements to build a uniquely strong M2M service delivery engine and solve problems of network dependence and signal loss.
Wiless Controls' Cellular Gateway has gone through rigorous beta testing. It has undergone evaluation in the United States and Canada, Europe, the Middle East and North Africa. Furthermore, Metropolitan Industries, the Company's production and distribution partner, has been demonstrating the Wiless M2M technology at their corporate headquarters in Romeoville, Illinois and has started displaying the technology in leading trade shows across the nation. Cellular Gateway is the proprietary device at the core of the Wiless M2M platform.
Wiless Controls, Inc. (WILS), closed Tuesday's trading session at $0.0485, up 21.25%, on 3,484,005 volume with 266 trades. The average volume for the last 60 days is 4,657 and the stock's 52-week low/high is $0.011/$0.45.
Cannabis Science, Inc. (CBIS)
Stock Analyzer reported today on Cannabis Science, Inc. (CBIS), SmallCap Network, Greenbackers, OTCJournal, OTCPicks, The Green Baron did earlier, and we highlight the Company, here at the QualityStocks Daily Newsletter.
Cannabis Science, Inc. is at the forefront of cannabinoid research and development for unmet medical needs. The Company works with leading experts in HIV drug development, medicinal characterization, and clinical research to develop, produce, and commercialize Phytocannabinoid-based pharmaceutical products. Cannabis Science™ has strong roots in - and an established relationship of trust with - the U.S. and Canadian medical cannabis patient communities. Cannabis Science is presently working on building a distinguished Scientific Advisory Board, adding to their Board of Directors, and appointing a Chief Medical Officer and a new Chief Scientific Officer. The Company is based in Colorado Springs, Colorado.
Cannabis Science's product, broadly described, is medical cannabis. This is a term which encompasses a wide spectrum of products. This ranges from plants grown by patients for their own use to pharmaceutical products developed from one or more of the cannabinoid compounds found in the whole cannabis plant. Cannabinoids are a group of terpenophenolic compounds present in Cannabis (Cannabis sativa L).
Currently, Cannabis Science is working with CBR International to develop a Pre-IND Application to the Food and Drug Administration (FDA), which focuses on the use of CS-S/BCC-1 topical cannabis-based preparations for the treatment of basal and squamous cell carcinomas. Concerning CS-S/BCC-1, Cannabis Science is currently working to develop preclinical investigations of CS-S/BCC-1 treatment of these carcinomas. The Company has started preclinical investigations, which are being initiated in Europe for Squamous/Basal Cell carcinomas and Kaposi's Sarcoma based on inhibition of carcinogenicity utilizing cannabinoids that have been demonstrated in recent studies to significantly affect tumour necrosis.
In March, Cannabis Science announced the appointment of Dr. Michael McGrath MD, PhD, Professor, Departments of Laboratory Medicine, Pathology, and Medicine at The University of California San Francisco (UCSF) to the Company's Scientific Advisory Board. Dr. McGrath has authored more than 100 scientific articles in the fields of AIDS, cancer and neurological disease since joining UCSF in 1985. He has recurring NIH funding to support his research programs in excess of $1.5M annually.
The targeting of Cannabis Science's CS-TATI-1 research program will be to newly diagnosed patients infected with drug resistant virus, treatment experienced patients with drug-resistant HIV strains, and those intolerant of currently available therapies. In addition, the Company will be pursuing other clinical research collaborations. These include the AIDS Clinical Trials Groups (ACTG), the Canadian AIDS Trial Network (CATN), and the European AIDS Trial Network (EATN).
Cannabis Science, Inc. (CBIS), closed Tuesday's trading session at $0.0636, up 7.25%, on 3,988,316 volume with 318 trades. The average volume for the last 60 days is 7,214,376 and the stock's 52-week low/high is $0.0305/$0.172.
Huldra Silver, Inc. (HDA.V)
We are reporting on Huldra Silver, Inc. (HDA.V) today, here at the QualityStocks Daily Newsletter.
Listed on the TSX Venture Exchange, Huldra Silver, Inc. (HDA.V) is a fully integrated silver mining, exploration and development company. Currently, the Company is mining at their Treasure Mountain Project in British Columbia (B.C.), Canada. In addition, Huldra Silver is assessing other opportunities for acquisition and development. The Company also lists on the OTC Markets' OTC Pink Current Information under the trading symbol "HUSIF ". Huldra Silver has their headquarters in Vancouver, B.C.
The Company's Treasure Mountain Project (100 percent owned, 7,000 acres) is three hours east of Vancouver. Huldra is utilizing an offsite mill for processing mill feed at their property outside of Merritt, B.C. In August of 2012, the Company started commissioning a new 200 tonne per day grinding, crushing and floatation mill at the Merritt facility.
On May 5, 2011, Huldra Silver purchased all of the shares of Craigmont Holdings Ltd. (now Huldra Holdings Ltd.). Huldra Holdings holds real property, mineral claims and mineral leases (the Mill Property) covering about 8,400 hectares, located in south central B.C, approximately 10 kilometers west of Merritt. The point of the acquisition was to build a mill facility on the permitted site of the former copper producing mine to process the ore from the Treasure Mountain Mine.
The Treasure Mountain Mine is a high-grade silver/lead/zinc vein hosted deposit. Currently, Treasure Mountain has more than 4,000 meters of underground development on four levels, over a vertical strike of 295 meters.
Since May of 2012, Huldra Silver has been underground mining under a 60,000 tonne per year small mines permit. They beforehand mined a 10,000 tonne bulk sample. Exploration activities are presently focusing on expanding the underground resource and defining additional mineralized structures on the mine property.
Last week, Huldra Silver announced that as of March 26, 2013, the Company has achieved commercial production based on current production levels. Huldra will be providing production accounting and cash flow statements for the second quarter of 2013. The Company continues to see considerable monthly increases in production and shipments of concentrates.
In the first lot period of March 2013 (March 1 to March 15) 92.58 dry metric tonnes of lead/silver concentrate and 131.24 dry metric tonnes of zinc concentrate were shipped to the smelter. In the second lot period (March 16 to March 31), an estimated 73 dry metric tonnes of lead/silver concentrate and 38 dry metric tonnes of zinc concentrate were shipped to the smelter.
Huldra Silver, Inc. (HDA.V), closed Tuesday's trading session at $0.77, up 5.48%, on 138,500 volume. The stock's 52-week low/high is $0.62/$1.77.
Zenyatta Ventures Ltd. (ZEN.V)
Today we are highlighting Zenyatta Ventures Ltd. (ZEN.V), here at the QualityStocks Daily Newsletter.
Zenyatta Ventures Ltd. is a junior exploration company based in Thunder Bay, Ontario. The Company is currently developing a unique Graphite deposit and exploring for base metal deposits on the Albany Project in Northeastern Ontario. Cliffs Natural Resources presently holds 12.7 percent interest in Zenyatta Ventures. Cliffs is an international mining and natural resources company.
Graphite is a natural form of carbon with the chemical formula C that it shares with diamond and coal. Graphite is now considered one of the more strategic elements by several leading industrial nations. Graphite has growing importance in high technology manufacturing and in the up-and-coming "green" industries.
Zenyatta Ventures' Albany Project (Arc of Fire) is in the James Bay Lowlands. Recent advances in airborne geophysics have allowed for deeper penetration/resolution to identify EM Anomalies for drilling. The area is large enough to host and hide world-class deposits. The area has sizeable exploration potential with easy access and low cost entry opportunities.
The Company is conducting exploration programs targeting nickel (Ni); copper (Cu), as well as Platinum Group Metals (PGMs) on the Albany Project. Furthermore, Zenyatta discovered the Graphite Deposit in the Albany Project area during their 2011 Drill Program. The graphite discovery is 30 kms north of the Trans Canada Highway and approximately 4 kms from an all-weather road.
Last week, the Company announced a drilling update on the Albany (Hydrothermal) Graphite Deposit. The first drill hole (Z13-4F10) intersected 363 meters (m) of graphite mineralization from 47.0 m to 410.0 m. This represents the widest zone of graphite material intersected to date on the Albany deposit.
Yesterday, Zenyatta Ventures announced that they were awarded the "Bernie Schnieders, Discovery of the Year" for the Albany Graphite Deposit. They were presented with the award in Thunder Bay, Ontario on April 2, 2013 by the Northwest Ontario Prospectors Association (NWOPA) to recognize an exceptional discovery in Ontario during 2012.
The TSX Venture Exchange recently announced the 2013 TSX Venture 50. The top performing company from the mining industry sector during 2012 is Zenyatta Ventures Ltd.
Zenyatta Ventures Ltd. (ZEN.V), closed Tuesday's trading session at $1.98, up 7.03%, on 447,497 volume. The stock's 52-week low/high is $0.15/$2.50.
Abakan, Inc. (ABKI)
RedChip reported this month on Abakan, Inc. (ABKI), and today we choose to highlight the Company, here at the QualityStocks Daily Newsletter.
Abakan, Inc. is an emerging leader in the advanced coatings and metal formulations markets. The Company develops, manufactures, and markets advanced nanocomposite materials, innovative fabricated metal products and highly engineered metal composites for applications in the oil and gas, petrochemical, mining, aerospace and defense, energy, infrastructure and processing industries. Abakan lists on the OTCQB; the Company has their corporate headquarters in Miami, Florida.
Abakan's mission is to become a leader in metal protection and life extension through assembling controlling interests in a small number of next-generation technology firms. The Company will also look for and invest in innovative technology and R&D firms to expand their share and segment control in the industry. Portfolio companies of Abakan include MesoCoat, Inc. and Powdermet, Inc.
Abakan operates from numerous locations in the U.S. and Canada. They intend on establishing international operations in South America, the Middle East, Asia and Russia. Currently, Abakan's technology portfolio includes high-speed large-area metal cladding technology, long-life nanocomposite anti-corrosion and-wear coating materials and high-strength lightweight metal composites.
At the beginning of April, Abakan announced that their proprietary CermaClad™ clad pipe product was awarded the "Subsea Pipeline Technology of the Year" award by the Pipeline Industries Guild. MesoCoat, the Abakan subsidiary that developed the CermaClad™ technology, received the award at the Pipeline Industries Guild National Dinner in London on March 12, 2013. The CermaClad™ high-speed large-area clad pipe technology produces an advanced metallurgical clad pipe product for the oil and gas industry, where availability of metallurgical clad pipes and the associated lead-time have been a foremost concern.
Yesterday, Abakan announced that they entered into A Memorandum of Understanding (MOU) with Cone S.A. for construction of a manufacturing facility to suit large-scale clad pipe manufacture inside the new Suape Export Processing Zone (Suape EPZ) in Pernambuco State, Brazil. The large-scale, 4-line clad pipe manufacturing plant will be capable of producing up to $200 million of clad products each year.
The facility will assist in meeting the demand for corrosion-resistant clad pipe to enable the safe and efficient production of oil in Brazil. More than 80 percent of oil fields are highly sour in Brazil. The construction of the Brazil facility represents the first step in Abakan's plan to build corrosion-resistant clad pipe manufacturing facilities around the world.
Abakan, Inc. (ABKI), closed Tuesday's trading session at $2.82, up 4.83%, on 68,339 volume with 95 trades. The average volume for the last 60 days is 14,916 and the stock's 52-week low/high is $1.35/$2.99.
Loans4Less.com, Inc. (LFLS)
The QualityStocks Daily Newsletter would like to spotlight Loans4Less.com, Inc. (LFLS). Today, Loans4Less.com, Inc. closed trading at $0.15, even for the day, on 5,000 volume with 2 trades. The stock’s average daily volume over the past 60 days is 5,797, and its 52-week low/high is $0.01/$0.39.
Loans4Less.com, Inc. was pleased to report being ranked as one of the top loan producers by dollar volume for all of last year today by leading industry publication, Origination News, with loan volume of $104M in 309 loans. Chairman and President of LFLS, Steven M. Hershman, was proud of the way the company has advance broader operations without compromising the quality of current services and outreach, asserting that the company is not only on track for expansion of the brand but actively pursuing JVs to duplicate the success of their origination model in California.
Loans4Less.com, Inc. (LFLS) is an online mortgage broker which matches qualified individuals seeking mortgage loans with suitable lenders who offer the company a competitive wholesale lending program. Maintaining an A+ TrustLink rating with the Better Business Bureau, the company provides competitive rates, terms, costs, daily updates, extensive market information, and trusted first-class service to the public.
Leveraging its portfolio of 62 different web domains, Loans4Less.com is focused on developing a national consumer platform for conforming residential mortgage programs and implementation of other consumer loan programs via operating providers. The company's expansion strategy includes rapidly growing revenues through strategic and cost-effective advertising, licensing, and/or third party agreements that build national recognition of the Loans4Less® brand.
The management team has accumulated many years of experience in the real estate and financial services sectors. This combination of expertise provides the knowledge and foresight necessary to get the best results for the company and their thousands of loyal clients. The team skillfully navigated through the credit crisis that destroyed much of their competition, putting the company in a stronger position to increase market share.
Loans4Less.com is not exposed to the risks and/or problems that are associated with sub-prime lending. Having never defaulting on an obligation or been involved in any litigation, the company is poised for rapid growth in today's low interest rate environment with its industry leading reputation and well established relationships with respected lenders. Disclaimer
Loans4Less.com, Inc. Company Blog
Loans4Less.com, Inc. News:
Loans4Less.com Ranked in List as a Top Residential Loan Originator 2012
Loans4Less.com Expects to Achieve Fully Reporting Status by 2014
Loans4Less.com Launches New Advertising Campaign to Reach a Potential 1.7 Million
Rafarma Pharmaceuticals, Inc. (RAFA)
The QualityStocks Daily Newsletter would like to spotlight Rafarma Pharmaceuticals, Inc. (RAFA). Today, Rafarma Pharmaceuticals, Inc. closed trading at $0.55, up 7.84%, on 34,250 volume with 27 trades. The stock’s average daily volume over the past 60 days is 2,828, and its 52-week low/high is $0.0501/$0.98.
Rafarma Pharmaceuticals, Inc. (RAFA) is a multiproduct pharmaceutical company specializing in the production of generic antibiotics and specialty pharmaceuticals, including its own proprietary products approved by the ministry of health. Rafarma stands as one of the most ambitious projects in recent medical history, having constructed the most technologically advanced pharmaceutical plant in Russia.
Based in Terbuny, Lipetsk region, Russia, Rafarma possesses a unique niche in the burgeoning pharmaceutical market and is poised to become a major player in the international drug industry. The company was established under the auspices of the Foundation to Support Health Care and has been approved by the Ministry of Health.
Rafarma recently received the general license for pharmaceutical products and began manufacturing three new products: Sodium Para-Aminosalicilate, Ibuprofen, and Betagistin. Receiving the general license was one of the final steps the company needed to open its new plant in Terbuniv, and Rafarma has been named one of only four national strategic pharmaceutical suppliers to the Russian Federation.
Advances in health care science, medicine, and technology have increased the general life expectancy of Eastern European citizens steadily over the past decade. Elderly citizens, which comprise the largest portion of the pharmaceuticals market, have bolstered demand for pharmaceuticals nationwide. Rafarma is well positioned to capitalize on the expanding industry with its strong relationships and state-of-the-art production facility. Disclaimer
Rafarma Pharmaceuticals, Inc. Company Blog
Rafarma Pharmaceuticals, Inc. News:
Rafarma Pharmaceuticals Registers CEFTRIAXONE Under International Label
Rafarma Pharmaceuticals, Inc. Receives General License for Pharmaceutical Products and has Started to Manufacture 3 New Products
Rafarma Pharmaceuticals, Inc. Named 1 Of 4 National Strategic Pharmaceutical Suppliers To The Russian Federation
Rainbow Coral Corp. (RBCC)
The QualityStocks Daily Newsletter would like to spotlight Rainbow Coral Corp. (RBCC). Today, Rainbow Coral Corp. closed trading at $0.125, up 19.05%, on 633,240 volume with 51 trades. The stock’s average daily volume over the past 60 days is 158,217, and its 52-week low/high is $0.10/$2.67.
Rainbow Coral Corp. (RBCC), via wholly owned subsidiary Rainbow Biosciences, continually seeks out new partnerships with biotechnology developers to deliver profitable new medical technologies and innovations. The company specifically pursues opportunities that offer short-term marketability and commercialization potential in key areas like Alzheimer's, Parkinson's, and Cancer.
Bioscience technology is a growing, dynamic field of innovation that applies life processes to practical uses, such as the manufacturing of medical devices and the development of new bioscience procedures. From pharmaceuticals to pacemakers, genetically engineered plants to gene therapy, bioscience technology can be found virtually anywhere.
The pending joint venture with Amarantus BioScience to develop and market new therapies and treatments for neurological diseases and physical traumas is a great example of the initiatives underway. In recent news, Amarantus licensed a highly promising diagnostic blood test that could become an invaluable new tool in Alzheimer's clinical trials where patient recruitment errors occur often due to inaccurate diagnosis.
The global biotech industry, currently valued at more than $84.6B, allows new players with bright ideas to quickly grab market share and create completely new markets. The exciting initiatives being driven forward by Rainbow Coral promise to transition today's leading-edge research into practical, affordable treatments for people who need them most. Disclaimer
Rainbow Coral Corp. Company Blog
Rainbow Coral Corp. News:
RBCC Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market
RBCC: New Rainbow BioSciences Website Highlights Impressive Deal Flow
RBCC TheraKine Joint Venture Offers Significant Opportunity in Licensing
Advaxis, Inc. (ADXS)
The QualityStocks Daily Newsletter would like to spotlight Advaxis, Inc. (ADXS). Today, Advaxis, Inc. closed trading at $0.0929, up 4.38%, on 1,164,722 volume with 57 trades. The stock’s average daily volume over the past 60 days is 3,776,813, and its 52-week low/high is $0.0275/$0.155.
Advaxis, Inc. (ADXS) is a clinical-stage biotechnology company developing the next-generation of immunotherapies for cancer and infectious diseases. The company’s immunotherapies are based on a novel platform technology that uses live, bio-engineered bacteria to secrete an antigen/adjuvant fusion protein that redirects the powerful immune response all human beings have to fight off cancer and disease.
The company has more than fifteen distinct constructs in various stages of development, all of which are involved in strategic collaborations with recognized centers of excellence such as the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
Advaxis’ lead construct, ADXS-HPV, is currently in Phase 2 clinical development for recurrent/refractory and advanced cervical cancer, CIN 2/3, and HPV caused head and neck cancers. This important construct was recognized as the Best Therapeutic Vaccine (approved or in development) at the 5th Annual Vaccine Industry Excellence (ViE) Awards by the vaccine industry and the journal Expert Reviews of Vaccines.
The estimated global market for immunotherapies is projected to exceed $37.2B by 2012, with cancer vaccines forecast to grow into an $8B market. Protected by 77 issued and pending patents, Advaxis is extremely well positioned to capitalize on the burgeoning opportunities in the healthcare sector as it advances the development of next-generation treatments for today’s most challenging diseases. Disclaimer
Advaxis, Inc. Company Blog
Advaxis, Inc. News:
Advaxis Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop
Advaxis Nominated for Best Early-Stage Vaccine Biotech at 6th Annual Vaccine Industry Excellence Awards
Advaxisí ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma
What does your typical due diligence look like? Pouring over earnings, contacting investor relations, compiling industry statistics, and scanning message boards and newsletters? When considering the investment of your hard-earned money into a company, would you go so far as to take a trip to its physical location? What if the company is headquartered overseas?
QualityStocks managing director Michael McCarthy has set a high bar for due diligence on behalf of the investment community, boarding a plane to fly more than 6,000 miles to Southern Moscow to see Rafarma Pharmaceuticals’ sprawling 270,000 square-foot pharmaceutical production facility for himself.
It may seem like a drastic measure until you consider the skepticism reverse-merger Chinese companies have triggered in the small-cap space in recent years. In 2011, toxicity from illicit reverse-merger companies bled through the Chinese sector and prompted an SEC bulletin warning investors of potential fraud in the arena and how to avoid it. The ordeal left a foul residue on the entire Chinese sector and overseas-based small caps in general, whether they were derived from reverse-merger or not. But the potential of one Russia-based pharmaceutical was enough to spark the interest of McCarthy, who responded to Rafarma’s invite and loaded up the QualityStocks camera crew to fully vet the management and operations of the company on its own soil.
“This client stands out because its state-of-the-art pharmaceutical plant has taken four years of persistent effort and massive investment to get to this point. The other side is that with the onslaught of all the funky China deals, Russia-based companies are often met with skepticism from investors,” McCarthy stated. “On paper Rafarma’s plant looks amazing, but looks can be deceiving. So we brought our camera crew to produce an HD video of the facility, which we will share with investors very soon.”
Rafarma is a Russia-based multi-product pharmaceutical company producing generic antibiotics and specialty pharmaceuticals in addition to its own line of proprietary products that are approved by the Ministry of Health of Russian Federation. The company recently constructed a world-class manufacturing facility capable of producing all types and forms of medical drugs of various pharmacological groups.
Rafarma is located in the economic zone of Terbunsky, Russia, roughly 300 km south of Moscow, the highly modernized megacity boasting more than 11.5 million residents. The city is the financial epicenter of Russia, with many business sectors, including pharmaceuticals, achieving outstanding growth rates as the Russian government executes a comprehensive strategy to encourage domestic growth and minimize the nation’s dependence on foreign medicines.
Rafarma’s state-of-the-art pharmaceutical plant has been supported by the government of Lipetsk region of Russia, the Ministry of Health of Russian Federation, and the Ministry of Industry and Trade of Russian Federation, which listed Rafarma as one of the leading and most prospective projects in the modern Russian pharmaceutical and medical industry. All this sounds impressive on paper, but the real value lies in the impressive brick and mortar facility itself.
The three-level facility is surrounded by guards and barbed wire, which are reinforced by security checkpoints and key card access throughout the entire facility. What struck McCarthy first and foremost was the sheer size of the facility. Rafarma owns 75 acres, 5 of which are occupied by the company’s manufacturing plant. The remaining acreage serves as a cushion against land lock, and also provides ample room for future expansion. Because the facility is located in an economic zone, when the plant is fully operational it will be exempt from paying local taxes for the first five years of operations.
“Most pharmaceutical plants in the United States and Europe are geographically bound by land lock,” McCarthy stated. “Rafarma, however, has acres and acres of land that will allow it to expand in the future. The Russian pharmaceutical industry is reaching new heights and Rafarma has provided itself the opportunity to grow with it.”
It took two hours for McCarthy and his team to see the entire facility. Rafarma management walked them through different labs and production facilities, which McCarthy describes as immaculately clean, sterile and secure.
“When you see the video the QualityStocks team is producing, you will get a good feel for the plant and its size. But when you’re there in person, hearing and seeing the machines, walking the halls and laboratories, it is absolutely stunning. You’ve got to see it to believe it,” he said.
Once the facility is in full operations, it will be a buzzing honeycomb mass producing pharmaceutical products through the entire manufacturing process – from the actual making of the drugs to each pill being sealed in blister packs and shot down a conveyer belt and into packaging where they are boxed, labeled and ready to be shipped out.
As of now Rafarma has 125 employees on its payroll, though the company anticipates increasing its number of employees up to 400 as manufacturing gets underway.
“These guys have the space, equipment and means to run the full spectrum of pharmaceutical operations. From manufacturing to packaging and shipment, they are very close to getting clearance to have all systems on go,” McCarthy explained.
The company’s manufacturing facility is GDP and GDP compliant, and GCP and GMP standards are in their last stages of approval. Rafarma is also working to become GLP compliant, at which time it will be the only Russia-based pharmaceutical company representing the complete cycle of the world’s highest pharmaceutical standards (Good Distribution Practice, Good Clinical Practice, Good Manufacturing Practice, Good Laboratory Practice).
Rafarma anticipates being completely compliant to industry standards and fully operational by the summer of 2013. The company’s goals are to produce high-quality pharmaceutical products for the domestic market, aiming to reduce prices on certain pharmaceutical products by 30%-40%.
The company is already considered the principle supplier to the Russian Public Health system and the Russian Army, is backed by the biggest bank in Russia, and has invested roughly 100 million euros in its own facilities.
McCarthy notes that big pharmaceutical companies will be drawn to Rafarma’s ability to offer flexibility in meeting mass demand since the company’s facility has the ability to both increase in physical size and maximize capacity.
“This is the Ferrari of pharmaceutical plants,” he said. “The general concern regarding overseas investment may cause some to hesitate, but I believe long term this is going to be a fantastic story. The management team is highly professional and focused. I’m thinking millions of potential profits for these guys long term – they are definitely one-of-a kind.”
Back in the United States, QualityStocks’ media production team is editing hours of video footage of Rafarma’s manufacturing facility and management interviews to produce high-definition videos that fully encapsulate Rafarma’s state-of-the art manufacturing facility and relay its legitimacy, opportunity, and enormity in the best way possible, short of an actual visit to the site. The first trip to Rafarma’s facility was enough to warrant another trip, which QualityStocks has planned later this year to observe the production facility in full swing.
“If Rafarma Pharmaceuticals continues to do what it’s doing and we at QualityStocks can continue to help them grow, we’re going to have a fantastic relationship,” McCarthy stated.
For more information on Rafarma Pharmaceuticals, visit www.rafarma.com
Loans4Less.com, an online mortgage loan brokerage firm focused on Conforming loans, today announced it has been ranked by Origination News as one of the top 2012 loan producers by dollar volume.
Loans4Less.com recorded loan volume of $104 million on a total of 309 loans issued last year. The publicly traded online mortgage loan brokerage was ranked in the top third, taking place 66 out of 200 top residential mortgage loan originators in the United States,
Steven M. Hershman, Chairman & President of Loans4Less.com, stated, “We have diligently worked to advance broader operations without compromising the quality of current services and outreach. Being ranked in the top third of the list of leading loan producers is testament to our commitment to the Company, our customers and our shareholders. We intend to maintain this upward trend as we continue to increase the value of the Loans4Less.com brand.”
As previously announced, the company is pursuing opportunities to offer its loan services to customers outside the State of California, focusing on proven marketing strategies and business practices.
“We are on track to expand our Loans4Less.com brand and seek JV Partner(s) to duplicate our [California] origination model in other states and in the meantime we are focused on the two most important rules for a long-term superior success rate, ‘better before cheaper and revenue before cost,’” [per article in Harvard Business Review, April 2013].
For more information on the company, visit www.Loans4Less.com
Minnesota-based Urologix, Inc. is a market leader of minimally invasive medical products for both the relief and treatment of the symptoms and obstructions caused by Benign Prostatic Hyperplasia (BPH). Founded in 1991, the company currently develops, markets, manufactures, and distributes urological products that provide lasting relief for symptoms due to BPH.
Yesterday, Urologix announced that it has reached a significant milestone in its licensing agreement with Medtronic. Through this agreement Urologixwill now manufacture the Prostiva RF Therapy System, a registered trademark of Medtronic. The agreement allows for the rights to sell all Prostiva RF Therapy products under the Urologix brand nationwide. Working directly with Prostiva’s manufacturing partners, Urologix will reinforce quality and standards of excellence.
Intermixing the Prostiva® RF Therapy System alongside the innovative Urologix’ Cooled ThermoTherapy™, Urologix is now the company behind two leading in-office BPH technologies. The Prostiva® RF Therapy System reduces prostate tissue to help relieve overall BPH symptoms. The Urologix Cooled ThermoTherapy™ enhances patient comfort by means of a cooling mechanism that helps to protect the surrounding healthy tissue. Both systems help to provide safe revilement of the symptoms or obstructions caused by BPH. The Cooled ThermoTherapy™ family also includes Urologixproducts such as Targis®, CoolWave®, the CTC Advance®, and the Targis® catheter families.
For more information, please visit www.urologix.com
Unilife is a developer and commercial supplier of injectable drug delivery systems. The company’s portfolio of proprietary device technologies includes prefilled syringes with automatic needle retraction, drug reconstitution delivery systems, auto-injectors, wearable injectors, and targeted drug delivery systems.
The company reported today that it signed a customization and commercial supply agreement with a U.S. pharmaceutical company for the EZMix dual-chamber syringe. Unilife will supply the customer with a customized device from its platform of EZMix dual-chamber delivery systems for use with a lyophilized drug that requires mixing at the time of injection.
Unilife expects to generate revenues immediately and garner up to $110 million in revenues during the 15-year agreement period. This figure is based upon a customization and production scale-up program, commercial device sales, and a royalty of net drug sales. The customer’s drug is in late-stage clinical development and the customer plans an accelerated path to gain U.S. regulatory approval.
The customer has agreed to pay Unilife about $3 million over a 12-24 month period for the customization and supply of prefilled EZMix devices. The company will receive an additional $3 million to fund the production scale-up of high-volume assembly equipment to manufacture the customized device in commercial volumes.
Unilife will also receive royalty payments (representing roughly a third of the $110 million total) on net annual commercial revenue for the drug in exchange for the customer securing worldwide exclusivity to EZMix for its target drug. The agreement includes a guaranteed minimum annual royalty payment that the customer must provide to Unilife.
For additional information about Unlife and its portfolio of injectable drug delivery products, visit www.unilife.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) Announces Abstract Accepted for Oral Presentation at SITC Cancer Immunotherapy Clinical Trials Workshop
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Receives ISO Certification for Excellagen
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces Fourth Quarter and Full Year 2012 Financial Results
- International Stem Cell Corp. (ISCO) Announces Fourth Quarter 2012 Financial Results and Provides Business Update
- Loans4Less.com, Inc. (LFLS) Ranked in List as a Top Residential Loan Originator 2012
- Rafarma Pharmaceuticals, Inc. (RAFA) Registers CEFTRIAXONE Under International Label
- Rainbow Coral Corp. (RBCC) Targets Companion Diagnostics Opportunities in Booming $232 Billion Personalized Medicine Market
- Soul and Vibe Interactive Inc. (SOUL) to Pursue Business Development Deals at Game Connection Conference in San Francisco
- The Aristocrat Group Corp. (ASCC) The Aristocrat Group Corp. (ASCC)
- The Guitammer Company Inc. (GTMM) Joins D-Tools Manufacturer Vantage Point (MVP) Program
- VentriPoint Diagnostics Ltd. (VPTDF) Applies for European and Canadian Approvals for A New Application for Non-Specific Heart Disease
- Viaspace, Inc. (VSPC) Insiders Extend Lock-up of Shares
- Viscount Systems, Inc. (VSYS) Freedom Access Control Technology Secures Dallas High Rises
- VistaGen Therapeutics, Inc. (VSTA) to Present Enhancements and Expanded Validation of LiverSafe 3Dô at Society of Toxicology's 52nd Annual Meeting